Cariprazine is an atypical antipsychotic medication primarily used in the treatment of schizophrenia and bipolar disorder. It belongs to the class of dopamine D3/D2 receptor partial agonists, with a higher affinity for D3 receptors. This unique receptor profile helps improve both positive and negative symptoms of schizophrenia. Cariprazine also exhibits partial agonist activity at serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It plays an important role in stabilizing dopamine activity in the brain, reducing psychotic symptoms while minimizing side effects. The drug is effective in managing manic, mixed, and depressive episodes associated with bipolar disorder. Cariprazine has a long half-life due to its active metabolites, allowing for once-daily dosing. It is generally well tolerated when used as prescribed under medical supervision. Careful dose adjustment is required to avoid adverse effects. Overall, cariprazine represents an advanced therapeutic option in modern psychiatric treatment.
